Opexa Therapeutics 4Q Loss Widens
Opexa Therapeutics' 4th-Quarter Loss Widens on Higher Research and Development Costs
March 18, 2008: 09:22 AM EST
NEW YORK (Associated Press) - Biotechnology company Opexa Therapeutics Inc. said Tuesday its 2007 loss widened on higher research and development expenses.
The company lost $14.7 million, or $2.19 per share, compared with a loss of $12.6 million or $2.35 per share. The company had no revenue in 2007 or 2006. Opexa had about 1.3 million additional shares in 2007.
Opexa did not report fourth-quarter results.
Research and development expenses rose 70 percent to about $13.1 million, primarily due to midstage studies of the company's experimental multiple sclerosis treatment Tovaxin.
More details can be found at this page.
Tim provided some info on the "going concern" statement last November in this thread. Opexa's recent round of fund raising should carry them through the end of this year. Hopefully, the results of the current phase IIB study will get more investors on line so that they can successfully complete a phase III.
Hoping for good results,
Holy S**t. I'm sorry for you and your site mates. I have not heard any stories about anyone being dropped. Maybe its time to keep a really close ear to the ground. Big ??????????'s
Bob, Can you imagine a scenario where all 5 patient would go from RR to Progressive at the same site at the same time. I can't.
- Similar Topics
- Last post